Claire Pomeroy - Becton Dickinson Independent Director
| BDX Stock | USD 233.15 0.94 0.40% |
Director
Ms. Claire Pomeroy is Independent Director of the Company. Since 2013, she has served as the President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, Dr. Pomeroy served as Dean of the University of California, Davis School of Medicine, and Chief Executive Officer of the UC Davis Health System. Dr. Pomeroy also is Chair of the Board of Directors of the Foundation for Biomedical Research and the Sierra Health Foundation, and Vice Chairman of the Board of Trustees of The New York Academy of Medicine. She is a member of the Board of Trustees of the New York Blood Center and the Morehouse School of Medicine since 2014.
| Age | 65 |
| Tenure | 10 years |
| Address | 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 |
| Phone | 201 847 6800 |
| Web | https://www.bd.com |
Becton Dickinson Management Efficiency
The company has Return on Asset of 0.0312 % which means that on every $100 spent on assets, it made $0.0312 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0513 %, implying that it generated $0.0513 on every 100 dollars invested. Becton Dickinson's management efficiency ratios could be used to measure how well Becton Dickinson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. At this time, Becton Dickinson's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 53.3 B in 2024, whereas Intangible Assets are likely to drop slightly above 603.1 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dipchand Nishar | Guardant Health | N/A | |
| Stanley Meresman | Guardant Health | 71 | |
| Heidi Fields | Agilent Technologies | 60 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| Martiny Harris | Thermo Fisher Scientific | 59 | |
| Richard Reese | Charles River Laboratories | 75 | |
| Dow Wilson | Agilent Technologies | 61 | |
| R Keith | Thermo Fisher Scientific | 52 | |
| Craig Thompson | Charles River Laboratories | 64 | |
| George Scangos | Agilent Technologies | 72 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| Frances Arnold | Illumina | 61 | |
| Judy Lewent | Thermo Fisher Scientific | 71 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| Robert Bertolini | Charles River Laboratories | 59 | |
| Caspar Tudor | Waters | N/A | |
| Francis deSouza | Illumina | 53 | |
| Edward Conard | Waters | 63 | |
| Martin Harris | Thermo Fisher Scientific | 61 | |
Management Performance
| Return On Equity | 0.0513 | ||||
| Return On Asset | 0.0312 |
Becton Dickinson Leadership Team
Elected by the shareholders, the Becton Dickinson's board of directors comprises two types of representatives: Becton Dickinson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Becton. The board's role is to monitor Becton Dickinson's management team and ensure that shareholders' interests are well served. Becton Dickinson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Becton Dickinson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Reidy, Chief Financial Officer, Executive Vice President, Chief Administrative Officer | ||
| Denise Fleming, Executive Officer | ||
| Ellen Strahlman, Chief Medical Officer, Senior Vice President - Research and Development | ||
| Willard Overlock, Independent Director | ||
| Rebecca Rimel, Independent Director | ||
| Thomas Spoerel, Senior Vice President, Controller and Chief Accounting Officer, Principal Accounting Officer | ||
| Gary Cohen, Executive VP | ||
| Claire Fraser, Independent Director | ||
| Alexandre Conroy, Executive Vice President, Chief Integrated Supply Chain Officer | ||
| John Gallagher, VP of Corporate Fin., Treasurer and Controller | ||
| Ami Simunovich, Regulatory Quality | ||
| James Orr, Independent Director | ||
| Monique Dolecki, IR Contact Officer | ||
| Jeffrey Henderson, Independent Director | ||
| John DeFord, Executive Vice President, Chief Technology Officer | ||
| Greg Rodetis, Head Relations | ||
| Christopher Jones, Independent Director | ||
| Jeffrey Sherman, Senior Vice President General Counsel | ||
| Edward DeGraan, Independent Director | ||
| Antoinette Segreto, Senior Taxes | ||
| Claire Pomeroy, Independent Director | ||
| Patrick Kaltenbach, Executive Vice President, President - Life Sciences | ||
| Michael Garrison, Executive segment | ||
| Catherine Burzik, Independent Director | ||
| Nabil Shabshab, Senior Vice President Chief Marketing Officer | ||
| Claudia Curtis, Chief VP | ||
| Linda Tharby, Segment President — Life Sciences | ||
| Charles Bodner, Senior Vice President Corporate Finance, and Chief Accounting Officer and Principal Accounting Officer | ||
| R Eckert, Independent Director | ||
| William Kozy, COO and Executive VP | ||
| Roland Goette, Executive Vice President and Presidentident - EMEA | ||
| James Lim, Executive Vice President and President, Greater Asia | ||
| Basil Anderson, Independent Director | ||
| Antoine Ezell, Executive Vice President and Presidentident, North America and Chief Marketing Officer | ||
| Andrew Eckert, Independent Director | ||
| Thomas Polen, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer | ||
| Marshall Larsen, Lead Independent Director | ||
| Troy Kirkpatrick, VP PR | ||
| Stephen Sichak, Senior Vice President - Integrated Supply Chain | ||
| Alberto Mas, Executive Vice President and President - Life Sciences Segment | ||
| William Tozzi, Interim President - Interventional | ||
| Michelle Quinn, Executive Counsel | ||
| Carla Burigatto, Senior Officer | ||
| Shana Neal, Executive Officer | ||
| Alfred Sommer, Independent Director | ||
| Ching leong, Executive Vice President and President Greater Asia | ||
| Elizabeth McCombs, Executive Officer | ||
| Bertram Scott, Independent Director | ||
| FACC MD, Chief VP | ||
| Gary Mecklenburg, Independent Director | ||
| Samrat Esq, Public Devel | ||
| Henry Becton, Lead Independent Director | ||
| Francesca DeMartino, VP Relations | ||
| David Hickey, Executive Vice President and President, Life Sciences Segment | ||
| Betty Larson, Executive Vice President- Human Resources, Chief Human Resources | ||
| James Borzi, Executive Vice President - Global Operations, Chief Supply Chain Officer | ||
| William Brown, Independent Director | ||
| Simon Campion, Executive Vice President and President BD Interventional Segment | ||
| Carrie Byington, Independent Director | ||
| Vincent Forlenza, Chairman, CEO and President and Chairman of Executive Committee | ||
| Christopher DelOrefice, Chief Financial Officer, Executive Vice President | ||
| Jerome Hurwitz, Senior Vice President - Human Resources | ||
| Samrat Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel | ||
| David Melcher, Independent Director | ||
| Timothy Ring, Independent Director |
Becton Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Becton Dickinson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0513 | ||||
| Return On Asset | 0.0312 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 82.29 B | ||||
| Shares Outstanding | 288.9 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 89.20 % | ||||
| Number Of Shares Shorted | 2.93 M | ||||
| Price To Earning | 45.86 X |
Pair Trading with Becton Dickinson
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Becton Dickinson position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Becton Dickinson will appreciate offsetting losses from the drop in the long position's value.Moving against Becton Stock
| 0.43 | DYNT | Dynatronics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Becton Dickinson could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Becton Dickinson when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Becton Dickinson - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Becton Dickinson and to buy it.
The correlation of Becton Dickinson is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Becton Dickinson moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Becton Dickinson moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Becton Dickinson can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Becton Dickinson and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Becton Dickinson information on this page should be used as a complementary analysis to other Becton Dickinson's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Becton Stock analysis
When running Becton Dickinson's price analysis, check to measure Becton Dickinson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Becton Dickinson is operating at the current time. Most of Becton Dickinson's value examination focuses on studying past and present price action to predict the probability of Becton Dickinson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Becton Dickinson's price. Additionally, you may evaluate how the addition of Becton Dickinson to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Becton Dickinson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Becton Dickinson. If investors know Becton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Becton Dickinson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Dividend Share 3.68 | Earnings Share 4.36 | Revenue Per Share 67.719 | Quarterly Revenue Growth 0.026 |
The market value of Becton Dickinson is measured differently than its book value, which is the value of Becton that is recorded on the company's balance sheet. Investors also form their own opinion of Becton Dickinson's value that differs from its market value or its book value, called intrinsic value, which is Becton Dickinson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Becton Dickinson's market value can be influenced by many factors that don't directly affect Becton Dickinson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Becton Dickinson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Becton Dickinson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Becton Dickinson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.